Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents

Wael Shehta; Norah A. Alsaiari; Basant Farag; Marwa M. Abdel-Aziz; Shaker Youssif; Sherin M Elfeky; Samar El-Kalyoubi; Nermine A. Osman

doi:10.1055/s-0043-1775424

SynOpen, Table of Contents

CC BY 4.0 · SynOpen 2025; 09(01): 73-83
DOI: 10.1055/s-0043-1775424

paper

Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents

Authors

Wael Shehta

^aDepartment of Chemistry, Faculty of Science, Zagazig University, Zagazig, 44519, Egypt
Norah A. Alsaiari

^bDepartment of Chemistry, Faculty of Science and Arts at Sharurah, Najran University, Najran 11001, Saudi Arabia
Basant Farag

^aDepartment of Chemistry, Faculty of Science, Zagazig University, Zagazig, 44519, Egypt
Marwa M. Abdel-Aziz

^cMedical Microbiology at the Regional Center for Mycology and Biotechnology, Al-Azhar University, Cairo, Egypt
Shaker Youssif ∗

^aDepartment of Chemistry, Faculty of Science, Zagazig University, Zagazig, 44519, Egypt
Sherin M Elfeky

^dPharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, 355516, Egypt
Samar El-Kalyoubi

^ePharmaceutical Organic Chemistry, Faculty of Pharmacy, Port Said University, Port Said, 42511, Egypt
Nermine A. Osman

^fPharmaceutical Organic Chemistry, Faculty of Pharmacy, Zagazig University, Zagazig 44511, Egypt

Abstract

All articles of this category

Abstract

Condensation reaction of aromatic aldehydes with 2-(6-amino-2-chloropyrimidin-4-yl)isoindoline-1,3-dione and 2-(6-amino-2-hydrazineylpyrimidin-4-yl)isoindoline-1,3-dione afforded 2-(2-chloro-6-((3 alkylbenzylidene)amino) pyrimidin-4-yl)isoindoline-1,3-dione derivatives 6a–f and 2-(6-amino-2-(2-(arylidene)hydrazinyl)pyrimidin-4-yl)isoindoline-1,3-dione derivatives 8a–f, respectively, as phthalimide–aminopyrimidine hybrids. The compounds showed a wide range of antitubercular activities against sensitive MDR and XDR M. tuberculosis strains, with 8f and 6a showing the highest activity; these compounds inhibited sensitive M. tuberculosis with MIC of 0.48 and 0.98 μg/mL, respectively, comparable to isonizide (INH) (MIC = 0.12 μg/mL). Both 8f and 6a inhibited the MDR strain with MIC of 1.95 and 7.81 μg/mL, respectively, and XRD with MIC of 7.81 and 15.63 μg/mL, respectively. Both 8f and 6a inhibited mycobacterial InhA enzyme in vitro (IC₅₀ = 0.717± 0.033 μM and 1.646± 0.069 μM, respectively). Molecular docking simulations revealed that 8f and 6a were also capable of interacting at the catalytic site of the InhA enzyme via binding with NAD⁺ and Tyr158, in a manner similar to that of the native ligand. Compounds 6a and 8f exhibited physicochemical properties of oral bioavailable drug-like compounds with high gastrointestinal absorption. Predictions showed that the compounds are unlikely to have side effects on the CNS and no anticipated hepatotoxicity, mutagenicity, or acute oral toxicity was identified in models.

Key words

Mycobacterium tuberculosis - ADMET studies - docking simulation - enzyme inhibition - phthalimide–pyrimidine hybrids

Full Text

References

References
1 Modi P, Patel S, Chhabria M. Bioorg. Chem. 2019; 87: 240
2 Tiberi S, Muñoz-Torrico M, Duarte R, Dalcolmo M, D’Ambrosio L, Migliori G.-B. Pulmonology 2018; 24: 86
3 Augustynowicz-Kopeć E, Demkow U, Grzelewska-Rzymowska I, Korzeniewska-Koseła M, Langfort R, Michałowska-Mitczuk D, Rowińska-Zakrzewska E, Zielonka TM, Ziołkowski J, Zwolska Z. Adv. Respir. Med. 2013; 81: 323
4 Mondal R, Jain A. Emerging Infect. Dis. 2007; 13: 1429
5 Vale N, Gomes P, Santos HA. Curr. Drug Metab. 2013; 14: 151
6 Rawat R, Whitty A, Tonge PJ. Proc. Natl. Acad. Sci. U.S.A. 2003; 100: 13881
7 Takayama K, Wang C, Besra GS. Clin. Microbiol. Rev. 2005; 18: 81
8 AlMatar M, Makky EA, Var I, Kayar B, Köksal F. Pharmacol. Rep. 2018; 70: 217
9 Wang L.-Q, Falany CN, James MO. Drug Metab. Dispos. 2004; 32: 1162
10 He X, Alian A, Stroud R, Ortiz de Montellano PR. J. Med. Chem. 2006; 49: 6308
11 Ng PS, Manjunatha UH, Rao SP, Camacho LR, Ma NL, Herve M, Noble CG, Goh A, Peukert S, Diagana TT. Eur. J. Med. Chem. 2015; 106: 144
12 Pajk S, Živec M, Šink R, Sosič I, Neu M, Chung C.-w, Martínez-Hoyos M, Pérez-Herrán E, Álvarez-Gómez D, Álvarez-Ruíz E. Eur. J. Med. Chem. 2016; 112: 252
13 Yar MS, Siddiqui AA, Ali MA. J. Chin. Chem. Soc. 2007; 54: 5
14 Othman DI, Hamdi A, Abdel-Aziz MM, Elfeky SM. Bioorg. Chem. 2022; 124: 105809
15 Phatak PS, Bakale RD, Dhumal ST, Dahiwade LK, Choudhari PB, Siva Krishna V, Sriram D, Haval KP. Synth. Commun. 2019; 49: 2017
16 Rani A, Johansen MD, Roquet-Banères F, Kremer L, Awolade P, Ebenezer O, Singh P, Kumar V. Bioorg. Med. Chem. Lett. 2020; 30: 127576
17 Jesumoroti OJ, Beteck RM, Jordaan A, Warner DF, Legoabe LJ. Mol. Diversity 2023; 27: 753
18 Al-Soliemy AM, Sabour R, Farghaly TA. Med. Chem. 2022; 18: 181
19 Finger V, Kufa M, Soukup O, Castagnolo D, Roh J, Korabecny J. Eur. J. Med. Chem. 2023; 246: 114946
20 Kamal A, Adil S, Tamboli JR, Siddardha B, Murthy U. Lett. Drug Des. Discovery 2008; 5: 261
21 Malik MS, Adil SF, Seddigi ZS, Morad M, Jassas RS, Thagafi II, Altass HM, Jamal QM. S, Riyaz S, Alsantali RI. J. Saudi Chem. Soc. 2021; 25: 101226
22 Totawar P, Varala R, Kotra V, Pulle J. Curr. Chem. Lett. 2023; 12: 249
23 Pan P, Tonge P. Curr. Top. Med. Chem. 2012; 12: 672
24 Youssif S, El-Bahaie S, Nabih E. J. Chem. Res. 1999; 23: 112
25 Youssif S, Mohamed SF. Monatsh. Chem. 2008; 139: 161
26 Farag B, Agili F, El-Kalyoubi S, Said SA, Youssif S, Shehta W. ChemistrySelect 2022; 7: e202103834
27 Wang H, Wen K, Wang L, Xiang Y, Xu X, Shen Y, Sun Z. Molecules 2012; 17: 4533
28 Shehta W, Agili F, Farag B, Youssif S, Almehmadi SJ, Elfeky SM, El-Kalyoubi S. Future Med. Chem. 2023; 15: 661
29 Sivaraman S. Dissertation . State University of New York at Stony Brook; U.S.A.: 2002
30 Sabbah M, Mendes V, Vistal RG, Dias DM, Záhorszká M, Mikusova K, Korduláková J, Coyne AG, Blundell TL, Abell C. J. Med. Chem. 2020; 63: 4749
31 Elfeky SM, Sobahi TR, Gineinah MM, Ahmed NS. Arch. Pharm. 2020; 353: 1900211
32 Kamsri P, Hanwarinroj C, Phusi N, Pornprom T, Chayajarus K, Punkvang A, Suttipanta N, Srimanote P, Suttisintong K, Songsiriritthigul C. J. Chem. Inf. Model. 2019; 60: 226
33 Freundlich JS, Wang F, Vilchèze C, Gulten G, Langley R, Schiehser GA, Jacobus DP, Jacobs WR. Jr, Sacchettini JC. ChemMedChem 2009; 4: 241
34 Srivastava A. J. Xi’an Shiyou Uni., Nat. Sci. Ed. 2021; 17: 267
35 Paradkar MV, Gadre SY, Pujari TA, Khandekar PP, Kumbhar VB. Synth. Commun. 2005; 35: 471
36 Lu Y, Zheng M, Wang B, Fu L, Zhao W, Li P, Xu J, Zhu H, Jin H, Yin D. Antimicrob. Agents Chemother. 2011; 55: 5185
37 Elsayed ZM, Eldehna WM, Abdel-Aziz MM, El Hassab MA, Elkaeed EB, Al-Warhi T, Abdel-Aziz HA, Abou-Seri SM, Mohammed ER. J. Enzyme Inhib. Med. Chem. 2021; 36: 384

Supplementary Material

Supporting Information (PDF) (opens in new window)